Nanoencapsulation of chitooligosaccharides enhances its oral bioavailability and anti-liver fibrotic effects

Liu, Peng; Li, Heng; Ruiyi, Li; Geng, Yan; Gong, Jin‐Song; Xu, Huaxi; Xu, Zhenghong; Shi, Jin‐Song

doi:10.1016/j.foodres.2022.111471

Cited by 10 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mice were employed with good reliability and repeatability for modeling, which were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). 21 , 22 …”

Section: Methodsmentioning

confidence: 99%

“…Mice were treated according to previous methods. 21 , 22 Briefly, all groups of mice except the CTL group were treated with 20% CCl 4 solution in olive oil twice a week at a dosage of 4 mL kg −1 (i.p.) for 4 weeks to construct a hepatic fibrosis model, while mice in CTL group received the same volume of olive oil (i.p.).…”

Section: Methodsmentioning

confidence: 99%

“… 18 , 19 , 20 In our previous study, COS significantly ameliorated toxicity and liver function in carbon tetrachloride (CCl 4 )-induced hepatic fibrosis model. 21 , 22 However, little information is currently available on the metabolic modulation mechanism of COS in hepatopathy, reflected in the evaluation of the metabolic pathway by assessment of key proteins or genes. This has limited our knowledge on the ameliorative effect of COS on liver disease.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Aggravated hepatic fibrosis induced by phenylalanine and tyrosine was ameliorated by chitooligosaccharides supplementation

Liu,

Li,

et al. 2023

iScience

Self Cite

View full text Add to dashboard Cite

“…Mice were employed with good reliability and repeatability for modeling, which were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). 21 , 22 …”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Aggravated hepatic fibrosis induced by phenylalanine and tyrosine was ameliorated by chitooligosaccharides supplementation

Liu,

Li,

et al. 2023

iScience

Self Cite

View full text Add to dashboard Cite

“…The cell viability of neurons was about 91% when treated with both 5 µM of Aβ42 and 0.5 mg/mL of COS for 48 h. The cell viability of neurons decreased to 76% when exposed to 5 µM Aβ42 alone for 48 h [146]. Moreover, the encapsulated form of the CHOS showed enhanced bioavailability and alleviated liver fibrosis in mice by inhibiting the apoptosis of liver cells and angiogenesis [147].…”

Section: Other Applications Of Chos and Its Derivativesmentioning

confidence: 99%

Chitooligosaccharide and Its Derivatives: Potential Candidates as Food Additives and Bioactive Components

Mittal,

Singh,

Buatong

et al. 2023

Foods

View full text Add to dashboard Cite

Chitooligosaccharide (CHOS), a depolymerized chitosan, can be prepared via physical, chemical, and enzymatic hydrolysis, or a combination of these techniques. The superior properties of CHOS have attracted attention as alternative additives or bioactive compounds for various food and biomedical applications. To increase the bioactivities of a CHOS, its derivatives have been prepared via different methods and were characterized using various analytical methods including FTIR and NMR spectroscopy. CHOS derivatives such as carboxylated CHOS, quaternized CHOS, and others showed their potential as potent anti-inflammatory, anti-obesity, neuroprotective, and anti-cancer agents, which could further be used for human health benefits. Moreover, enhanced antibacterial and antioxidant bioactivities, especially for a CHOS-polyphenol conjugate, could play a profound role in shelf-life extension and the safety assurance of perishable foods via the inhibition of spoilage microorganisms and pathogens and lipid oxidation. Also, the effectiveness of CHOS derivatives for shelf-life extension can be augmented when used in combination with other preservative technologies. Therefore, this review provides an overview of the production of a CHOS and its derivatives, as well as their potential applications in food as either additives or nutraceuticals. Furthermore, it revisits recent advancements in translational research and in vivo studies on CHOS and its derivatives in the medical-related field.

show abstract

“…COS displays no toxic side efects on the liver and does not interfere with the lipid metabolism of normal rats [18]. Moreover, COS can counteract acetaminophen-induced liver injury and CCl 4induced liver fbrosis and damage [19][20][21] while improving nonalcoholic fatty liver disorder and relieving lipid accumulation and infammation [22,23]. Luo et al showed that COS protects L02 cells from acute alcohol exposure by activating nuclear factor-erythroid 2-related factor 2 (NRF2) and inhibiting the apoptotic pathway, suggesting that COS may protect against alcoholic injury [24].…”

Section: Introductionmentioning

confidence: 99%

The Preventative Effect of Chitooligosaccharides against Chronic Alcoholic Liver Disease by Regulating Alcohol Metabolism, Fatty Acid Metabolism, and Intestinal Barrier Damage

Li,

Zou,

Yin

et al. 2024

Journal of Food Biochemistry

View full text Add to dashboard Cite

Since chronic alcoholic liver disease (ALD) is a significant global health concern, several studies have shown that chitooligosaccharides (COS) exhibit hepatoprotective effects. This paper examined the COS protective effect on chronic ALD mice. Results showed that COS improved the lipid accumulation, liver injury, and oxidative stress levels in the mice while inhibiting cytochrome P450 protein 2E1 (CYP2E1) expression in the liver and promoting alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH1) expression, indicating that COS could ameliorate alcohol metabolism. Moreover, COS intervention also enhanced the antioxidant capacity of the liver and upregulated peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1), silent information regulator 1 (SIRT1), HO-1, and nuclear factor-erythroid 2-related factor 2 (NRF2) protein levels. In addition, COS increased peroxisome proliferator-activated receptor α (PPARα), acyl-CoA oxidase (ACOX), acyl-CoA synthetase long-chain family member (ACSL), carnitine palmitoyltransferase 1A (CPT-1A), and carnitine palmitoyltransferase 2 (CPT2) protein levels by upregulating the fatty acid β oxidation pathway and restoring mitochondrial genesis. From a liver-gut axis perspective, COS enhanced intestinal barrier function by increasing the adhesion junction (AJ) and intestinal tight junction (TJ) protein expression. Therefore, COS displayed a protective ability against chronic ALD. The results provide a theoretical basis for utilizing supplemental dietary COS as a functional food alternative for treating chronic ALD.

show abstract

Nanoencapsulation of chitooligosaccharides enhances its oral bioavailability and anti-liver fibrotic effects

Cited by 10 publications

References 33 publications

Aggravated hepatic fibrosis induced by phenylalanine and tyrosine was ameliorated by chitooligosaccharides supplementation

Aggravated hepatic fibrosis induced by phenylalanine and tyrosine was ameliorated by chitooligosaccharides supplementation

Chitooligosaccharide and Its Derivatives: Potential Candidates as Food Additives and Bioactive Components

The Preventative Effect of Chitooligosaccharides against Chronic Alcoholic Liver Disease by Regulating Alcohol Metabolism, Fatty Acid Metabolism, and Intestinal Barrier Damage

Contact Info

Product

Resources

About